Rfxank-KO Mouse
Common Name
Rfxank-KO
제품 ID
S-KO-04083
Backgroud
C57BL/6JCya
품종 계통계통 ID
KOCMP-19727-Rfxank-B6J-VA
상태
이 마우스 계통을 논문에서 사용할 경우, “Rfxank-KO Mouse (카탈로그 번호 S-KO-04083)은 Cyagen에서 구입하였습니다.”라고 명시해 주시기 바랍니다.
구매 가능한 제품 종류
연령
Genotype
성별
수량
표준 제공 조건은 최소 3마리의 이형접합(heterozygous) 보균자를 보장합니다. 동형접합(homozygous) 보균자 및/또는 특정 성별에 대한 브리딩 서비스도 제공됩니다.
기본 정보
품종 계통
Rfxank-KO
품종 계통계통 ID
KOCMP-19727-Rfxank-B6J-VA
유전자명
제품 ID
S-KO-04083
유전자 별칭
Tvl1
배경
C57BL/6JCya
NCBI ID
변형 내용
Conventional knockout
염색체
Chr 8
Phenotype
Datasheet
적용 분야
--
품종 계통 설명
Ensembl 전사체 ID
ENSMUST00000212320
NCBI 전사체 ID
NM_011266
타겟 영역
Exon 3~6
유효 영역 크기
~2.0 kb
유전자 연구 개요
RFXANK, the regulatory factor X-associated ankyrin-containing protein, is a crucial subunit of the heterotrimeric RFX complex. This complex is involved in the regulation of the transcription of major histocompatibility complex class II (MHC II) molecules in antigen-presenting cells, which is essential for the proper functioning of the immune system [3,5,6,7,8,9]. It also interacts with RFX7 and caspase-2, potentially playing roles in natural killer cell-mediated immunity, neuron development, and MHC II gene regulation [2,4].
Mutations in the RFXANK gene account for over 70% of known patients with MHC II deficiency worldwide. Homozygous loss-of-function mutations in RFXANK can cause bare lymphocyte syndrome (BLS) type II, and the associated phenotype has been expanded to include progressive neurodegenerative disease, with MRI showing global cerebral and cerebellar atrophy [1,3,6]. Patients with RFXANK mutations often present with later onset and diagnosis compared to those with RFX5 mutations in MHC-II deficiency [5].
In conclusion, RFXANK is essential for the regulation of MHC II molecule transcription, playing a key role in immune function. The discovery of its association with neurodegenerative disease through studies of patients with RFXANK mutations broadens our understanding of its functions. Understanding RFXANK's role can potentially aid in early diagnosis, prognosis refinement, and treatment strategies for MHC-II deficiency-related diseases [1,3,5].
References:
1. Alharby, Essa, Obaid, Mona, Elamin, Mohammed A O, Alasmari, Ali, Almontashiri, Naif A M. 2021. Progressive Ataxia and Neurologic Regression in RFXANK-Associated Bare Lymphocyte Syndrome. In Neurology. Genetics, 7, e586. doi:10.1212/NXG.0000000000000586. https://pubmed.ncbi.nlm.nih.gov/33855173/
2. Gao, Jun, Xu, Chao. 2019. Structural basis for the recognition of RFX7 by ANKRA2 and RFXANK. In Biochemical and biophysical research communications, 523, 263-266. doi:10.1016/j.bbrc.2019.12.059. https://pubmed.ncbi.nlm.nih.gov/31864703/
3. Cai, Yu Qing, Zhang, HangHu, Wang, Xiang Zhi, Shu, YingYing, Tang, Lan Fang. 2020. A Novel RFXANK Mutation in a Chinese Child With MHC II Deficiency: Case Report and Literature Review. In Open forum infectious diseases, 7, ofaa314. doi:10.1093/ofid/ofaa314. https://pubmed.ncbi.nlm.nih.gov/32875002/
4. Forsberg, Jeremy, Li, Xinge, Akpinar, Birce, Zhivotovsky, Boris, Olsson, Magnus. 2018. A caspase-2-RFXANK interaction and its implication for MHC class II expression. In Cell death & disease, 9, 80. doi:10.1038/s41419-017-0144-y. https://pubmed.ncbi.nlm.nih.gov/29362422/
5. Gulec Koksal, Zeynep, Bilgic Eltan, Sevgi, Topyildiz, Ezgi, Karakoc Aydiner, Elif, Baris, Safa. 2024. MHC Class II Deficiency: Clinical, Immunological, and Genetic Insights in a Large Multicenter Cohort. In The journal of allergy and clinical immunology. In practice, 12, 2490-2502.e6. doi:10.1016/j.jaip.2024.06.046. https://pubmed.ncbi.nlm.nih.gov/38996837/
6. Abolnezhadian, Farhad, Dehghani, Razieh, Dehnavi, Sajad, Khodadadi, Ali, Shohan, Mojtaba. . A novel mutation in RFXANK gene and low B cell count in a patient with MHC class II deficiency: a case report. In Immunologic research, 68, 225-231. doi:10.1007/s12026-020-09141-9. https://pubmed.ncbi.nlm.nih.gov/32578129/
7. Mousavi Khorshidi, Mohadese Sadat, Seeleuthner, Yoann, Chavoshzadeh, Zahra, Shahrooei, Mohammad, Parvaneh, Nima. 2023. Clinical, Immunological, and Genetic Findings in Iranian Patients with MHC-II Deficiency: Confirmation of c.162delG RFXANK Founder Mutation in the Iranian Population. In Journal of clinical immunology, 43, 1941-1952. doi:10.1007/s10875-023-01562-z. https://pubmed.ncbi.nlm.nih.gov/37584719/
8. Wiszniewski, Wojciech, Fondaneche, Marie-Claude, Louise-Plence, Pascale, Fischer, Alain, Lisowska-Grospierre, Barbara. 2003. Novel mutations in the RFXANK gene: RFX complex containing in-vitro-generated RFXANK mutant binds the promoter without transactivating MHC II. In Immunogenetics, 54, 747-55. doi:. https://pubmed.ncbi.nlm.nih.gov/12618906/
9. Chakraborty, Madhumita, Sengupta, Amitava, Bhattacharya, Dipankar, Banerjee, Subrata, Chakrabarti, Abhijit. 2010. DNA binding domain of RFX5: interactions with X-box DNA and RFXANK. In Biochimica et biophysica acta, 1804, 2016-24. doi:10.1016/j.bbapap.2010.07.009. https://pubmed.ncbi.nlm.nih.gov/20637319/
품질 관리 기준
정자 검사
동결 보존 전: 정자 농도 측정 및 정자 생존율 평가.
동결 보존 후: 각 배치에서 동결 보존된 정자 바이알 1개를 선택하여 체외수정(in vitro fertilization)에 사용합니다.
Environmental Standards:
SPFAvailable Region:
GlobalSource:
Cyagen문의하기
맞춤형 동물 모델 관련 상담을 위해 Cyagen 전문가와 연락해 보세요. 아래 양식을 작성하여 상담을 시작하거나 견적을 요청하시기 바랍니다.
Cyagen은 고객님의 개인정보를 소중히 여깁니다. 최신 제품, 서비스 및 인사이트를 안내드리고자 합니다. 고객님의 수신 설정은 다음과 같습니다:
해당 커뮤니케이션은 언제든지 수신 거부하실 수 있습니다. 수신 거부 방법 및 데이터 보호에 대한 자세한 내용은 개인정보처리방침을 참고해 주시기 바랍니다.
아래 버튼을 클릭함으로써, 요청하신 콘텐츠 제공을 위해 본 양식을 통해 제출된 개인정보를 Cyagen이 저장 및 처리하는 데 동의하게 됩니다.
